Global

Investors

CSL Share Price


Price Chart 
View CSL's share price performance over a 12 month period.

Financial Calendar 2014
12 Feb - Half Year Results
13 Aug - Full Year Results
15 Oct - AGM
Questions about my Shareholding
Please call CSL's share registry ComputerShare on 1800 646 882 for queries regarding address changes, dividend payments, etc.
Investor Contact
Mark Dehring
Mark Dehring
Head of Investor Relations
Phone: +613 9389 2818
mark.dehring@csl.com.au
Subscribe to News Alert
To receive the latest updates about CSL, sign up for our email News Alert.

About CSL

CSL Limited has over 10,000 staff in more than 20 countries. We produce many life-saving and life-enhancing medicines that enable thousands of people around the world to lead normal healthy lives. Our headquarters is in Australia and we have substantial manufacturing operations in the US, Germany and Switzerland.

CSL is a global specialty biopharmaceutical company that researches, develops, manufactures and markets biotherapies to treat and prevent a range of human medical conditions. We produce safe and effective therapies for patients who rely on them for their quality of life, and sometimes for life itself.

ASX Releases

18/11/2014
CSL112 Found to Elevate Cholesterol Efflux in Patients with Coronary Artery Disease and Mechanism for Rapid Cholesterol Efflux Capacity Demonstrated
Two research studies presented today at the American Heart Association Scientific Sessions in Chicago provide further understanding of the mechanisms by which CSL112, a novel formulation of apolipoprotein A-1 (apoA-1), may reduce the high incidence of early recurrent cardiovascular events seen in post MI patients. Early recurrent cardiovascular events are associated with high morbidity and mortality, and reducing early events is an important target for new therapies. More.

13/11/2014
New €350 Million Private Placement
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that on 12 November 2014 it closed a new €350 million private placement in the U.S. The private placement was foreshadowed in CSL’s full year announcement in August 2014. More.

10/11/2014
CSL Limited Launches AEGIS-I, a Phase 2b Clinical Study of CSL112, a Novel Apolipoprotein A-I Infusion Therapy Designed to Rapidly Remove Cholesterol from Arteries and Stabilize Plaque
CSL Limited today announced the launch of AEGIS-I, a Phase 2b clinical study of CSL112, a novel formulation of apolipoprotein A-I (apoA-I). Administered as a short series of weekly infusions, CSL112 is designed to rapidly remove cholesterol from the arteries and stabilize lesions at risk of rupture. This represents a new approach to reduce the high incidence of early recurrent cardiovascular events in the days and weeks following a heart attack. More.

27/10/2014
CSL to acquire Novartis influenza vaccine business
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that it has agreed to acquire Novartis’ global influenza vaccine business for US$275 million. The business will be combined with CSL’s subsidiary, bioCSL. More.

15/10/2014
CSL announces new A$950m share buyback
CSL Limited (ASX:CSL) today announced a new on-market share buyback of up to A$950 million. More.

13/08/2014
Full Year Results announcement for 2013/14
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$1,307 million for the full year ended 30 June 2014, up US$96 million or 8% on a reported basis when compared to the prior comparable period (PCP). The result includes a one-off U.S. antitrust class action litigation settlement. Earnings per share (EPS) grew 11%, benefiting from current and past capital management initiatives. More.

12/02/2014
Half Year Results announcement for 2013/14
CSL Limited (ASX:CSL) today announced a net profit after tax (NPAT) of US$646 million for the six months ended 31 December 2013, up US$21 million or 3% on a reported basis when compared to the prior comparable period (PCP). The result included a one-off U.S. antitrust class action litigation settlement of US$64 million, or US$39 million after tax. More.

Prior ASX Releases

>> View the ASX Archive


Share
LinkedIn Twitter Facebook Google+